GH35 Tablets for Advanced Solid Tumors: A Study on Safety and Early Results

Phase 1 Unknown 18 enrolled Suzhou Genhouse Bio Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

Evaluate the safety and tolerability of GH35 in patients with KRAS mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in patients with KRAS mutant advanced solid tumors.

Timeline

Start: 2021-09-27
Primary completion: 2023-03-22
Completion: 2025-12-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GH35	Unknown	—	Oral

GH35 Tablets for Advanced Solid Tumors: A Study on Safety and Early Results

Summary

Timeline

Drugs

Indications